Following on from information provided to NICE by the company in January 2019, the appraisal of Leukaemia (acute myeloid, IDH2 positive) - enasidenib (after 2 therapies) was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued.
| Status | Discontinued |
| Technology type | Medicine |
| Decision | Selected |
| Process | TA |
| ID number | 1455 |
Email enquiries
- If you have any queries please email scheduling@nice.org.uk
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 16 November 2022 | Discontinued. Following on from information provided to NICE by the company in January 2019, the appraisal of Leukaemia (acute myeloid, IDH2 positive) - enasidenib (after 2 therapies) was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued. |
| 06 October 2020 | The Department for Health and Social Care has asked NICE to conduct an appraisal of enasidenib for treating IDH2-positive acute myeloid leukaemia after 2 or more therapies. However, the company have advised that the European Medicines Agency Committee for Medicinal Products (CHMP) have issued a negative opinion for enasidenib for treating IDH2-positive acute myeloid leukaemia after 2 or more therapies. Therefore, NICE has decided to suspend this appraisal from its work program. As this appraisal has been referred to NICE we will continue to monitor any development and will update interested parties if the situation changes. |
| 01 February 2019 | Suspended. The company has informed NICE that it will not provide an evidence submission for this appraisal. Therefore, we are suspending the appraisal while we consider the next steps |
| 31 July 2017 | In progress. Topic referred |
| 13 July 2017 | Referral |
For further information on our processes and methods, please see our CHTE processes and methods manual